Vedolizumab Archives - Medical Conferences

LOVE-CD: Vedolizumab yields better outcomes in early than in late CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

LOVE-CD

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:24

Risankizumab influences key pathogenic Th17 cells in CD

Presented By

Dr Daniele Noviello, University of Milan, Italy

Trial

SEQUENCE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD

Presented By

Dr Ronen Stein, Children's Hospital of Philadelphia, USA

Trial

VEDOKIDS

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:54

Biologicals and JAK inhibitors hold promise in microscopic colitis

Presented By

Dr Bram Verstockt, University Hospitals Leuven, Belgium

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:35

How effective is dose escalation of biologicals in IBD?

Presented By

Dr Cristina Rubín de Célix, University Hospital La Princesa, Spain

Trial

RAINBOW-IBD

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:30

EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease

Presented By

Prof. Marc Ferrante, KU Leuven, Belgium

Trial

EVOLVE

Conference

DDW 2023

Type

News article

13 June 2023 13:56

Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure

Presented By

Prof. Mathurin Fumery, Amiens University Hospital, France

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:55

Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD

Presented By

Prof. Geert D’Haens , Academic Medical Center University of Amsterdam, the Netherlands

Trial

REPREVIO

Conference

ECCO

Type

Peer-reviewed article

4 May 2023 16:28

Better results for vedolizumab in early CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 4, LOVE-CD

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:19

Comparable safety profiles of biological therapies in elderly patients with IBD

Presented By

Dr Gustavo Drügg Hahn, McGill University Health Center, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:22

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By

Prof. Shomron Ben-Horin, Tel-Aviv University, Israel

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:21

Vedolizumab first approved therapy for chronic pouchitis

Presented By

Prof. Simon Travis, University of Oxford, UK

Trial

Phase 4, EARNEST

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:53

VEDOKIDS: Vedolizumab seems effective in paediatric IBD

Presented By

Dr Dan Turner, Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Israel

Trial

VEDOKIDS

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:51

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:46

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:44

Subcutaneous infliximab versus subcutaneous vedolizumab in IBD

Presented By

Prof. Laurent Peyrin-Biroulet, Nancy University Hospital, France

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:41

Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis

Presented By

Dr Bernd Bokemeyer, University Hospital Schleswig-Holstein, Germany

Trial

VEDO-IBD

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:37

ECCO 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECCO 2022

8 March 2022 10:18

Risk of hospitalisation and surgery linked to IBD biological

Presented By

Dr Camilla Bjørn Jensen, Frederiksberg Hospital

Conference

ECCO 2021

Type

News article

2 July 2021 20:20

Effects of vedolizumab versus adalimumab on QoL

Presented By

Dr E.V. Loftus, Mayo Clinic, USA

Trial

VARSITY

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:39

Vedolizumab and anti-TNF therapies: a real-world comparison

Presented By

Dr G. Mantzaris , Evangelismos Hospital, Greece

Trial

EVOLVE

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:35

Vedolizumab, adalimumab, and golimumab compared

Presented By

Dr F.S. Macaluso & Dr A. Casanotti

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:32

Vedolizumab versus ustekinumab

Presented By

Dr H. Alric & Dr V. Biemans

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:28

Subcutaneous vedolizumab maintenance therapy in CD

Presented By

Prof. S. Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, VISIBLE 2

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:11

Vedolizumab treatment persistence and safety

Presented By

Dr S. Danese & Dr N.A. Cohen, Humanitas University, Milan, Italy

Trial

GEMINI

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:04

Pipeline of IBD drugs

Presented By

Prof. W. Sandborn, University of California San Diego, USA

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 13:55

Impact of biologicals on faecal microbiota

Presented By

C. Caenepeel, KU Leuven, Belgium

Conference

ECCO 2020

14 April 2020 10:20

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By

Dr Evelyne Vinet, McGill University, Montreal, Canada

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:12

Vedolizumab superior to adalimumab in ulcerative colitis

Presented By

Dr Stefan Schreiber, University-Hospital Schleswig-Holstein, Germany

Trial

Phase 3, VARSITY

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 22:57

Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD

Presented By

Dr. Paccou, Amiens University Medical Center, France

Conference

EULAR 2018

Type

Peer-reviewed article

24 August 2018 23:43

Combining new drugs with different mechanisms

Trial

EXPLORER

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:31

Vedolizumab in anti-TNF-naïve IBD patients and safety profile

Trial

GEMINI

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:04

ILC1 distribution predicts response to ustekinumab

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 22:58

Vedolizumab induces endoscopic remission and healing in refractory CD

Trial

VERSIFY

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 19:50

Higher rates of remission and healing with vedolizumab vs TNF antagonist

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 17:57

Comparative effectiveness of vedolizumab and ustekinumab in CD

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 16:01